EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access

Assessing the Impact of Dermatophytosis on Quality of Life Using the Dermatology Life Quality Index: A Real-World Cross-Sectional Study From India

Priyanka Singh, Manjunath Shenoy, Mukesh Girdhar, Shrichand G Parasramani, Anupam Das, Pallavi S Mishra, Dhiraj Dhoot, Saiprasad Patil

Cureus · 01.04.2026

DOI: 10.7759/cureus.106253 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Cureus, erschienen am 01.04.2026. Verfasst von Priyanka Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology, Younique Skin Clinic, New Delhi, IND. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Dermatophytosis has emerged as a chronic, recurrent, and high-burden dermatosis in India, with increasing reports of extensive involvement and treatment difficulty. Although clinical assessment is routinely performed, patient-reported quality of life (QoL) evaluation is inconsistently integrated into practice. This multicentric real-world study aimed to assess the QoL burden associated with dermatophytosis using the Dermatology Life Quality Index (DLQI). METHODS: A cross-sectional study was conducted between April and October 2025 involving clinically diagnosed dermatophytosis patients attending the outpatient department from 325 centres across India with Independent Ethics Committee approval. The primary endpoint of the study was to assess DLQI in these patients, whereas secondary endpoints included evaluation of the association between DLQI scores and demographic, clinical, occupational, comorbidity-related, and treatment-related variables. RESULTS: We analysed the data of 2776 patients who met the inclusion criteria, highlighting the predominance of males (57%). The median DLQI was 12 (interquartile range (IQR) 8-17), indicating a very large impact of dermatophytosis on daily life. The QoL impairment increased progressively with disease extent, demonstrating a clear severity impact correlation relationship between lesion burden and DLQI (p

Schlagwörter

Stichwörter der Autor:innen

chronic dermatophytosisdermatology life quality indexfrom indiaquality of life (qol)recalcitrant diseaserecurrent dermatophytosissuper-bioavailable itraconazolesuperficial fungal infectionstopical antifungal

Autor:innen und Institutionen

  • Dermatology, Younique Skin Clinic, New Delhi, IND.
  • Dermatology, Yenapoye Medical College, Mangalore, IND.
  • Dermatology, Max Super Specialty Hospital, Patparganj, New Delhi, IND.
  • Dermatology, Anisha Clinic, Mumbai, IND.
  • Dermatology, KPC Medical College and Hospital, Kolkata, IND.
  • Global Medical Affairs, Glenmark Pharmaceuticals Ltd., Mumbai, IND.

Zitieren

APA

Singh, P., Shenoy, M., Girdhar, M., Parasramani, S. G., Das, A., Mishra, P. S., Dhoot, D., & Patil, S. (2026). Assessing the Impact of Dermatophytosis on Quality of Life Using the Dermatology Life Quality Index: A Real-World Cross-Sectional Study From India. Cureus. https://doi.org/10.7759/cureus.106253

Vancouver

Singh P, Shenoy M, Girdhar M, Parasramani SG, Das A, Mishra PS, et al. Assessing the Impact of Dermatophytosis on Quality of Life Using the Dermatology Life Quality Index: A Real-World Cross-Sectional Study From India. Cureus. 2026. doi:10.7759/cureus.106253

BibTeX
@article{Singh2026,
  author = {Singh, Priyanka and Shenoy, Manjunath and Girdhar, Mukesh and Parasramani, Shrichand G and Das, Anupam and Mishra, Pallavi S and Dhoot, Dhiraj and Patil, Saiprasad},
  title = {Assessing the Impact of Dermatophytosis on Quality of Life Using the Dermatology Life Quality Index: A Real-World Cross-Sectional Study From India},
  journal = {Cureus},
  year = {2026},
  doi = {10.7759/cureus.106253}
}
Kostenlos starten →